ORETICYL FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORETICYL FORTE (ORETICYL FORTE).
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
| Metabolism | Primarily excreted unchanged in urine; minimal hepatic metabolism |
| Excretion | Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces. |
| Half-life | Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours. |
| Protein binding | Hydrochlorothiazide: 40-68% bound to albumin. Deserpidine: ~95% bound to plasma proteins. |
| Volume of Distribution | Hydrochlorothiazide: 3-4 L/kg (distributes into erythrocytes). Deserpidine: 1-2 L/kg. |
| Bioavailability | Oral: Hydrochlorothiazide 65-75%; Deserpidine ~50% (extensive first-pass metabolism). |
| Onset of Action | Oral: 2-3 hours for diuresis; 3-6 days for antihypertensive effect. |
| Duration of Action | Diuresis: 6-12 hours; antihypertensive: persists 1-2 weeks after discontinuation. |
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR < 30 mL/min. For GFR 30-50 mL/min, reduce HCTZ dose to 12.5-25 mg daily; deserpidine may accumulate, use with caution. |
| Liver impairment | Child-Pugh A: No adjustment needed. Child-Pugh B: Use with caution; reduce deserpidine dose by 50%. Child-Pugh C: Avoid use. |
| Pediatric use | Not recommended for children due to lack of safety data; if used, HCTZ: 1-2 mg/kg/day in 1-2 divided doses, maximum 50 mg/day; deserpidine: 0.01-0.02 mg/kg/day, maximum 0.5 mg/day. |
| Geriatric use | Initiate at half the standard dose (HCTZ 25 mg/deserpidine 0.25 mg daily) due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and potassium levels closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORETICYL FORTE (ORETICYL FORTE).
| Breastfeeding | Thiazides are excreted in breast milk in low concentrations; M/P ratio unknown. May suppress lactation. Use with caution in breastfeeding women; monitor infant for electrolyte disturbances. |
| Teratogenic Risk | First trimester: Limited human data; thiazide diuretics cross placenta; risk of fetal/neonatal electrolyte disturbances. Second and third trimesters: Associated with fetal/neonatal jaundice, thrombocytopenia, and electrolyte imbalances. Avoid use in pregnancy-induced hypertension due to decreased placental perfusion. |
■ FDA Black Box Warning
None
| Serious Effects |
["Anuria","Hypersensitivity to thiazides or sulfonamide-derived drugs"]
| Precautions | ["Hypokalemia","Hyperuricemia","Hyperglycemia","Photosensitivity","Systemic lupus erythematosus exacerbation"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, serum electrolytes (particularly potassium), renal function, and weight gain. Fetal monitoring via ultrasound for growth restriction and amniotic fluid volume. |
| Fertility Effects | No known direct effects on fertility. Thiazides may cause minor electrolyte imbalances that could theoretically affect reproductive function, but no clinical evidence of significant impact. |